These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 36366304)

  • 1. Access to COVID-19 Vaccines: A New Global Approach.
    Bouderhem R
    Vaccines (Basel); 2022 Oct; 10(11):. PubMed ID: 36366304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trade-Related Aspects of Intellectual Property Rights Flexibilities and Public Health: Implementation of Compulsory Licensing Provisions into National Patent Legislation.
    McGIVERN L
    Milbank Q; 2023 Dec; 101(4):1280-1303. PubMed ID: 37646392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intellectual Property and the Politics of Public Good during COVID-19: Framing Law, Institutions, and Ideas during TRIPS Waiver Negotiations at the WTO.
    Fischer SE; Vitale L; Agutu AL; Kavanagh MM
    J Health Polit Policy Law; 2024 Feb; 49(1):9-42. PubMed ID: 37522338
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Future of Epidemic and Pandemic Vaccines to Serve Global Public Health Needs.
    Farlow A; Torreele E; Gray G; Ruxrungtham K; Rees H; Prasad S; Gomez C; Sall A; Magalhães J; Olliaro P; Terblanche P
    Vaccines (Basel); 2023 Mar; 11(3):. PubMed ID: 36992275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improving Access to COVID-19 Vaccines: An Analysis of TRIPS Waiver Discourse among WTO Members, Civil Society Organizations, and Pharmaceutical Industry Stakeholders.
    Kohler J; Wong A; Tailor L
    Health Hum Rights; 2022 Dec; 24(2):159-175. PubMed ID: 36579316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COVID-19 Vaccine, TRIPS, and Global Health Diplomacy: India's Role at the WTO Platform.
    Chattu VK; Singh B; Kaur J; Jakovljevic M
    Biomed Res Int; 2021; 2021():6658070. PubMed ID: 34485525
    [TBL] [Abstract][Full Text] [Related]  

  • 7. International Collaboration to Ensure Equitable Access to Vaccines for COVID-19: The ACT-Accelerator and the COVAX Facility.
    Eccleston-Turner M; Upton H
    Milbank Q; 2021 Jun; 99(2):426-449. PubMed ID: 33650737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Managing the effect of TRIPS on availability of priority vaccines.
    Milstien J; Kaddar M
    Bull World Health Organ; 2006 May; 84(5):360-5. PubMed ID: 16710544
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Global COVID-19 Vaccine Inequity: Failures in the First Year of Distribution and Potential Solutions for the Future.
    Pilkington V; Keestra SM; Hill A
    Front Public Health; 2022; 10():821117. PubMed ID: 35321196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing the global vaccine supply chain: balancing intellectual property rights with post COVID-19 vaccine equity.
    Park SP; Lee HJ; Yu Y; Lee EYJ; Park YS
    BMJ Glob Health; 2023 Nov; 8(11):. PubMed ID: 38035734
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Does TRIPS (Agreement on Trade-Related Aspects of Intellectual Property Rights) prevent COVID-19 vaccines as a global public good?
    Haugen HM
    J World Intellect Prop; 2021 Jul; 24(3-4):195-220. PubMed ID: 34230807
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Needle in a Haystack? Human Rights Framing at the World Trade Organization for Access to COVID-19 Vaccines.
    Perehudoff K; Qazilbash H; de Vries KF
    Health Hum Rights; 2022 Dec; 24(2):141-157. PubMed ID: 36579306
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redressing COVID-19 vaccine inequity amidst booster doses: charting a bold path for global health solidarity, together.
    Rackimuthu S; Narain K; Lal A; Nawaz FA; Mohanan P; Essar MY; Charles Ashworth H
    Global Health; 2022 Feb; 18(1):23. PubMed ID: 35193616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of the institutional landscape and proliferation of proposals for global vaccine equity for COVID-19: too many cooks or too many recipes?
    Geiger S; McMahon A
    J Med Ethics; 2023 Aug; 49(8):583-590. PubMed ID: 34848492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Dilemma, causes and countermeasures of global health governance: taking COVID-19 Vaccines Global Access Facility as an example].
    Bai AY; Zhang B; Jiang Y; Qiao Y
    Zhonghua Liu Xing Bing Xue Za Zhi; 2022 Apr; 43(4):483-487. PubMed ID: 35443301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can we move beyond vaccine apartheid? Examining the determinants of the COVID-19 vaccine gap.
    Forman L; Jackson C; Fajber K
    Glob Public Health; 2023 Jan; 18(1):2256822. PubMed ID: 37715686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Global Intellectual Property Waiver is Still Needed to Address the Inequities of COVID-19 and Future Pandemic Preparedness.
    Amin T; Kesselheim AS
    Inquiry; 2022; 59():469580221124821. PubMed ID: 36124939
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global health diplomacy at the intersection of trade and health in the COVID-19 era.
    Chattu VK; Pooransingh S; Allahverdipour H
    Health Promot Perspect; 2021; 11(1):1-4. PubMed ID: 33758749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TRIPS waiver of COVID-19 vaccines: Impact on pharmaceutical industry and what it means to developing countries.
    Chaudhary T; Chaudhary A
    J World Intellect Prop; 2021 Nov; 24(5-6):447-454. PubMed ID: 34908905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analyzing the Morality of Owning and Suspending Patent Rights for COVID-19 Vaccines in the Light of Catholic Social Teaching.
    Ballano VO
    Linacre Q; 2022 Feb; 89(1):47-63. PubMed ID: 35321490
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.